GNTANasdaqBiological Products, (No Diagnostic Substances)
Genenta Science S.p.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$0.66−0.02 (-2.40%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
3.1%
1M of 23M shares
Institutional holders
9
2 new, 4 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Marco Nuzzo | 5,543,910 | 11.50% | 13D (active) amendment | May 29, 2026 |
| Pierluigi Paracchi | 2,302,516 | 9.80% | 13G (passive) amendment | Jan 25, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of GNTA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Eurizon Capital SGR S.p.A. | 360,000 | 1.54% | $662.40K | – | 0.00% |
| Allianz SE | 234,050 | 1.00% | $430.65K | – | 0.00% |
| SmartHarvest Portfolios, LLC | 43,856 | 0.19% | $80.70K | −90,591 | 0.03% |
| Virtu Financial LLC | 36,913 | 0.16% | $68 | New | 0.00% |
| Simplicity Wealth,LLC | 18,590 | 0.08% | $34.21K | +6,379 | 0.00% |
| Ground Swell Capital, LLC | 14,374 | 0.06% | $26.45K | New | 0.03% |
| GAMMA Investing LLC | 9,863 | 0.04% | $18.15K | −4,425 | 0.00% |
| UBS Group AG | 3,027 | 0.01% | $5.57K | −80 | 0.00% |
| Farther Finance Advisors, LLC | 3 | 0.00% | $6 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 9 | 1M | 3.1% | 2 / 1 | 3 / 4 | 0M | 0M |
| Q1 2026 | 11 | 1M | 4.4% | 3 / 2 | 2 / 7 | 0M | 2M |
| Q4 2025 | 15 | 3M | 11.6% | 9 / 2 | 1 / 0 | 2M | 0M |
| Q3 2025 | 6 | 1M | 2.4% | 2 / 1 | 0 / 1 | 0M | 0M |
| Q2 2025 | 5 | 1M | 2.3% | 1 / 1 | 1 / 1 | 0M | 0M |
| Q1 2025 | 5 | 1M | 2.3% | 2 / 2 | 0 / 1 | 0M | 0M |
| Q4 2024 | 4 | 0M | 1.5% | 1 / 0 | 0 / 2 | 0M | 0M |
| Q3 2024 | 5 | 0M | 1.5% | 0 / 2 | 0 / 0 | 0M | 0M |
| Q2 2024 | 5 | 0M | 1.5% | 1 / 1 | 2 / 1 | 0M | 0M |
| Q1 2024 | 5 | 1M | 2.4% | 1 / 2 | 2 / 0 | 0M | 0M |
| Q4 2023 | 4 | 1M | 3.6% | 1 / 2 | 0 / 0 | 0M | 0M |
| Q3 2023 | 3 | 0M | 2.0% | 0 / 0 | 0 / 1 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Pierluigi Paracchi | Chief Executive Officer, Director, 10% owner | 27,000 | 0.12% | May 5, 2026 |
| Francesco Galimi | CMO& Head of Development, Director | 0 | – | Apr 1, 2026 |
| Richard B. Slansky | Chief Financial Officer | 2,200 | 0.01% | Apr 1, 2026 |
| Giacomoantonio Paracchi | Director | 0 | – | Apr 1, 2026 |
| Armon Sharei | Director | 0 | – | Apr 1, 2026 |
| Miguel Maria Mutti | Director | 0 | – | Apr 1, 2026 |